Literature DB >> 9839109

High serum lipoprotein(a) levels in Korean type 2 diabetic patients with proliferative diabetic retinopathy.

C H Kim1, H J Park, J Y Park, S K Hong, Y H Yoon, K U Lee.   

Abstract

OBJECTIVE: To examine the possible association between serum lipoprotein(a) [Lp(a)] concentration and proliferative diabetic retinopathy (PDR) in Korean patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: A total of 412 Korean outpatients with type 2 diabetes were examined. Diabetic retinopathy was determined by an ophthalmologist using fundoscopic examination. Serum Lp(a) levels were measured by two-site sandwich enzyme-linked immunosorbent assay.
RESULTS: The patients with PDR had higher serum Lp(a) levels than those with no diabetic retinopathy or with nonproliferative diabetic retinopathy (NPDR). Multiple logistic regression analysis showed that high serum Lp(a) levels and the presence of diabetic nephropathy were independent variables having a statistically significant association with PDR.
CONCLUSIONS: Korean type 2 diabetic patients with PDR had higher serum Lp(a) levels versus those with no diabetic retinopathy or with NPDR. Although these results suggest that Lp(a) might play a role in the occlusion of retinal capillaries leading to PDR, further prospective studies are required to prove the causal relationship.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9839109     DOI: 10.2337/diacare.21.12.2149

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  2 in total

1.  Lipoprotein(a) in type 2 diabetic subjects and its relationship to diabetic microvascular complications.

Authors:  Radhakrishnan Chandni; Kollengode Parameswaran Ramamoorthy
Journal:  World J Diabetes       Date:  2012-05-15

2.  Lipoprotein(a) serum levels in diabetic patients with retinopathy.

Authors:  Giulia Malaguarnera; Caterina Gagliano; Claudio Bucolo; Marco Vacante; Salvatore Salomone; Michele Malaguarnera; Daniela Giovanna Leonardi; Massimo Motta; Filippo Drago; Teresio Avitabile
Journal:  Biomed Res Int       Date:  2013-06-05       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.